|Bid||1.50 x 400|
|Ask||2.25 x 200|
|Day's Range||1.77 - 1.89|
|52 Week Range||0.93 - 3.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2018 - Mar 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Both Infinity Pharmaceuticals and Synergy Pharmaceuticals closed in the red on Friday. Shares of Infinity closed down nearly 14% despite encouraging results ...
Research Desk Line-up: Spectrum Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
NATIONAL HARBOR, Md., Nov. 10, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) today reported Phase 1 clinical and translational data for IPI-549, an oral, selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor that targets immune-suppressive tumor macrophages.
NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Major Indexes pulled back on Thursday as investors digested earnings from JPMorgan Chase and Citigroup. The Dow Jones Industrial Average declined 0.14 percent ...
- Clinical and Translational Data from Monotherapy Dose-Escalation Component of Ongoing Phase 1/1b Study of IPI-549 in Patients with Advanced Solid Tumors to be Reported During an Oral Session - CAMBRIDGE, ...
CAMBRIDGE, Mass. , Oct. 10, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 2017 BIO Investor Forum on Tuesday, October 17, 2017 , at 10:45 a.m. PT ( 1:45 p.m. ...